https://pharminent.com/80442-2/ 2026-05-10T17:35:21Z Pharminent en 2026-05-10T17:34:15Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-may-9-2026/ 2026-05-10T15:27:29Z Pharminent en Week in Review • INTELLIGENCE BRIEF • May 9, 2026 2026-05-10T15:27:26Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-8-2026/ 2026-05-09T01:34:42Z Pharminent en Oncology Intelligence Digest • May 8, 2026 2026-05-09T01:34:38Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-may-8-2026/ 2026-05-08T22:07:22Z Pharminent en GLP-1 Competitive Market Digest • Weekly • May 8, 2026 2026-05-08T22:07:17Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-may-8-2026/ 2026-05-08T21:42:04Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • May 8, 2026 2026-05-08T21:41:59Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-8-2026/ 2026-05-08T21:39:11Z Pharminent en Strategic News Watch • May 8, 2026 2026-05-08T21:39:05Z Blog https://pharminent.com/lilly-gilead-lead-pharmas-ma-boom/ 2026-05-10T17:13:21Z Pharminent en Lilly, Gilead lead pharma's M&A boom 2026-05-08T13:29:00Z Blog https://pharminent.com/biogen-eisai-hit-with-3-month-delay-for-starting-subq-alzheimers-therapy/ 2026-05-10T17:13:24Z Pharminent en Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer's therapy 2026-05-08T12:42:56Z Blog https://pharminent.com/odyssey-launches-upsized-279m-ipo-seaport-docks-on-nasdaq/ 2026-05-10T17:13:27Z Pharminent en Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq 2026-05-08T12:29:00Z Blog https://pharminent.com/novos-ceo-champions-record-breaking-start-for-wegovy-pill-in-us-market/ 2026-05-10T17:13:27Z Pharminent en Novo's CEO champions "record-breaking start" for Wegovy pill in US market 2026-05-08T10:34:07Z Blog